Composition for the treatment of fistula

Patent metadata

Field	Value
Publication number	US-9763882-B2
Application number	US-201214348379-A
Country	US
Kind code	B2
Filing date	Oct 3, 2012
Priority date	Mar 10, 2011
Publication date	Sep 19, 2017
Grant date	Sep 19, 2017

Abstract

A composition for use in the treatment of fistula, the composition comprising activated carbon.

First claim

The invention claimed is:

1. A method for the treatment of fistula, the method comprising administering to a subject in need of such treatment a pharmaceutically effective amount of a composition consisting of particles of activated carbon, wherein the activated carbon is administered rectally as a dry dose, and wherein the activated carbon is driven into the rectum of the subject using a driving fluid.

2. A method according to claim 1 , wherein the activated carbon is of average particle size 0.05 mm to 1 mm.

3. A method according to claim 1 , wherein the activated carbon is of average particle size 0.15 mm to 1 mm.

4. A method for the treatment of fistula, the method comprising administering to a subject in need of such treatment a pharmaceutically effective amount of a composition consisting of particles of activated carbon wherein 85% or more of the activated carbon particles have diameter in the range from 0.089 mm to 0.3 mm, wherein the activated carbon is administered rectally as a dry dose, and wherein the activated carbon is driven into the rectum of the subject using a driving fluid.

5. A method according to claim 4 , wherein 85% or more of the activated carbon particles have diameter in the range from 0.152 mm to 0.297 mm.

6. A method according to claim 1 , wherein the fistula is rectal fistula.

7. A method according to claim 1 , wherein the amount of activated carbon administered is in the range from 450 μg to 10 g.

8. A method according to claim 1 , wherein the activated carbon is granular.

9. A method according to claim 1 , wherein 90% or more of the activated carbon particles have diameter in the range from 0.125 mm to 0.297 mm.

10. A method according to claim 1 , wherein 85% or more of the activated carbon particles have diameter in the range from 0.152 mm to 0.297 mm.

11. A method for the treatment of fistula, the method comprising administering to a subject in need of such treatment a composition consisting of a dry powder of activated carbon which is dust free, wherein the composition is administered rectally as a dry dose, and wherein the activated carbon is driven into the rectum of the subject using a driving fluid.

12. A method for the treatment of fistula, the method comprising administering to a subject in need of such treatment a composition consisting of a dry powder (a dry dose) of activated carbon of particle size 0.001 to 1 mm, wherein the composition is administered rectally, and wherein the activated carbon is driven into the rectum of the subject using a driving fluid.

13. A method according to claim 1 , wherein the activated carbon is of average particle size 0.02 to 1 mm.

14. A method according to claim 1 , wherein the activated carbon is of average particle size 0.15 mm to 0.3 mm.

15. A method according to claim 1 , wherein the fistula is anal fistula.

16. A method according to claim 1 , wherein the activated carbon is ground activated carbon having an irregular particle shape.

17. A method according to claim 1 , wherein the composition is administered using a disposable, rectally-insertable, cannula containing the composition.

18. The method of claim 1 , wherein the driving fluid is a liquid.

19. The method of claim 18 , wherein the driving fluid is water.

20. The method of claim 1 , wherein the driving fluid is a gas.

21. The method of claim 20 , wherein the driving fluid is air.

22. The method of claim 18 , wherein the activated carbon is of particle size 0.15 mm to 1 mm.

23. The method of claim 19 , wherein the activated carbon is of particle size 0.15 mm to 1 mm.

24. The method of claim 18 , wherein the activated carbon is of particle size 0.05 mm to 0.15 mm.

25. The method of claim 19 , wherein the activated carbon is of particle size 0.05 mm to 0.15 mm.

26. The method of claim 20 , wherein the activated carbon is of particle size 0.05 mm to 0.15 mm.

27. The method of claim 21 , wherein the activated carbon is of particle size 0.05 mm to 0.15 mm.

28. The method of claim 1 , wherein the treatment comprises closing the fistula.

29. The method of claim 1 , wherein the treatment comprises healing the fistula, wherein the healing comprises closing the fistula without discharge.

30. The method of claim 1 , wherein the activated carbon is administered twice daily.

31. The method of claim 30 , wherein the activated carbon is administered once in the morning and once in the evening.

32. The method of claim 30 , wherein the treatment comprises closing the fistula within eight weeks of commencing treatment.

33. The method of claim 1 , wherein the driving fluid is maintained separately from the driving fluid until immediately before the activated carbon is administered.

34. A method for the treatment of fistula in a subject in need thereof, the method comprising providing a device containing a formulation that consists of particles of activated carbon as a dry dose, and further contains the driving fluid maintained separately from the activated carbon; inserting the device into the rectum of the subject; and actuating the device to cause the activated carbon to be driven into the rectum of the subject by the driving fluid.

35. The method of claim 34 , wherein the activated carbon is of particle size 0.15 mm to 1 mm and the driving fluid is a liquid; or wherein the activated carbon is of particle size 0.05 mm to 0.15 mm and the driving fluid is a liquid or a gas.

36. The method of claim 35 , wherein the driving fluid is a liquid.

37. The method of claim 36 , wherein the driving fluid is water.

38. The method of claim 35 , wherein the driving fluid is a gas.

39. The method of claim 38 , wherein the driving fluid is air.

40. The method of claim 1 , wherein the treatment is continued for a period of at least 8 weeks.

41. The method of claim 40 , wherein the activated carbon is administered twice daily during the treatment period.

Assignees

• Ferring Bv
• Ferring Bv

Inventors

• Halskov Søren
• Ekelund Mats

Classifications

• A61P43/00

  Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00 · CPC title

• A61P1/00

  Drugs for disorders of the alimentary tract or the digestive system · CPC title

• A61M3/022

  Volume; Flow rate · CPC title

• A61K2300/00

  Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00 · CPC title

• A61K33/00

  Medicinal preparations containing inorganic active ingredients · CPC title